TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes

Erber R, Hartmann A, Beckmann M, Mackensen A, Kremer A, Reimann H, Hübner H, Hein A, Lux MP, Jud S, Häberle L, Gaß P, Volz B, Schulz-Wendtland R, Rübner M, Fasching P (2018)


Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 39

Pages Range: 236-240

Journal Issue: Suppl 2

DOI: 10.1007/s00292-018-0526-7

Abstract

BACKGROUND: The interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy. OBJECTIVES: Correlation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study. METHODS: Illustration of the TILGen study design. Assessment of TILs and correlation with pCR within this BC study. RESULTS: pCR was achieved in 38.4% (56/146) and associated with estrogen receptor/progesterone receptor negative (ER-/PR-) and HER2+ tumors. Lymphocytic predominant BC (LPBC) was found in 16.4% (24/146), particularly in ER-/PR- (ER-: 27.3% vs. ER+: 9.9%, PR-: 22.3% vs. PR+: 8.2%), large, and poorly differentiated BC. TILs were significantly correlated with pCR in multivariate analysis. In LPBC, pCR was achieved in 66.7%, whereas it was 32.8% in non-LPBC. CONCLUSIONS: First results confirm the influence of the human immune system on the response to NACT in HER2+ and triple negative BC. TSA-specific immunotherapy might improve the outcome in BC patients but there is an urgent need for comprehensive studies to further investigate this issue.

Authors with CRIS profile

Additional Organisation(s)

How to cite

APA:

Erber, R., Hartmann, A., Beckmann, M., Mackensen, A., Kremer, A., Reimann, H.,... Fasching, P. (2018). TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes. Pathologe, 39(Suppl 2), 236-240. https://dx.doi.org/10.1007/s00292-018-0526-7

MLA:

Erber, Ramona, et al. "TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes." Pathologe 39.Suppl 2 (2018): 236-240.

BibTeX: Download